Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.
Healthcare distributor Cencora (NYSE:COR) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.9% year on year to $83.73 billion. Its non-GAAP profit of $3.84 per share was 1.4% above analysts’ consensus estimates.
Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September quarter of fiscal 2025, compared to $0.02 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 15.0 percent to $3.84 in the fiscal fourth quarter. For fiscal year 2025, diluted GAAP EPS increased 5.7 percent to $7.96. For fiscal year 2025, adjusted diluted EPS increased 16.3 percent to $16.00.
Shares of healthcare distributor Cencora (NYSE:COR)
jumped 3.3% in the morning session after Mizuho analyst Steven Valiquette raised the price target on the company's shares. The price target was increased to $340 from $334, while the firm kept an 'Outperform' rating on the stock. This move signaled continued confidence in Cencora's market performance. Adding to the positive mood in the sector, a key peer, Cardinal Health, reported strong quarterly results and lifted its outlook for the year. Cardinal Health's revenue grew by 22% compared to the previous year, with earnings also showing significant growth.
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns,
and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
Even though Cencora (currently trading at $315 per share) has gained 10.8% over the last six months, it has lagged the S&P 500’s 22.9% return during that period. This might have investors contemplating their next move.
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Shares of healthcare distributor Cencora (NYSE:COR)
jumped 4.5% in the afternoon session after peer company McKesson raised its long-term earnings growth outlook, boosting investor sentiment across the pharmaceutical distribution sector.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors.
A select few continue to innovate and expand, setting themselves up for long-term success.
